Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

medicines value

This page shows the latest medicines value news and features for those working in and with pharma, biotech and healthcare.

NICE rejects Novartis migraine treatment Aimovig

NICE rejects Novartis migraine treatment Aimovig

Ahmad adds: “NICE does not consider impact of diseases on broader society when evaluating the cost-effectiveness of medicines. ... We believe this fails to capture the true value of medicines like Aimovig.

Latest news

  • NHS Long-term Plan welcomed – but warnings on staff and overpromising NHS Long-term Plan welcomed – but warnings on staff and overpromising

    UK pharma industry response. The new Long-term Plan coincides with the launch of a new five year Voluntary Pricing and Access Scheme (VPAS) covering branded medicines in the UK. ... He also hailed the introduction of the VPAS, saying it “should see the

  • FDA fast tracks Novartis’ SMA gene therapy FDA fast tracks Novartis’ SMA gene therapy

    Novartis and AveXis are proud to lead the way toward a modern healthcare system built on the tremendous value of truly innovative and transformative medicines that could bend the curve of ... life. We are committed to flexibly partnering with healthcare

  • New ‘voluntary’ UK pricing deal caps growth, but promises faster uptake New ‘voluntary’ UK pricing deal caps growth, but promises faster uptake

    Cutting-edge and best value medicines will be fast-tracked and we will cut our medicines bill by £930 million next year following tough but constructive negotiations with the pharmaceutical industry – ... This means that people across the UK should

  • Novartis sells off part of Sandoz portfolio Novartis sells off part of Sandoz portfolio

    Sandoz's chief executive Francis adds: “Sharpening our portfolio focus in the US allows us to devote more time and resources toward our strategy of bringing complex generics, value-added medicines ... and biosimilars to patients, creating higher value

  • Your excellent marketing team: let the world know about it Your excellent marketing team: let the world know about it

    From working co-operatively with healthcare professionals to supporting their educational needs, and from launching new medicines to creating added value services, PMEA aims to provide a channel for our ... Those who win also see the value that external

More from news
Approximately 2 fully matching, plus 121 partially matching documents found.

Latest Intelligence

  • The UK’s new five-year pricing agreement The UK’s new five-year pricing agreement

    Value assessment. More and faster NICE appraisals for new medicines including speeding up the appraisal of non-cancer medicines to be in line with cancer medicine appraisals – cost-effective new medicines ... Commercial arrangements. Opportunities for

  • Deal Watch October 2018

    Novartis. Deal Type. Deal with. Details. Value. Acquisition. Endocyte. Portfolio of products and technology for. ... Sandoz’s US business has retained its biosimilars, value‐added medicines and complex generics, including the ophthalmology products.

  • In conversation with Pfizer’s Erik Nordkamp In conversation with Pfizer’s Erik Nordkamp

    Pfizer is proud to have worked alongside the NHS supplying medicines for over six decades to support the provision of high-quality healthcare to everyone that is free at the point ... It is therefore essential that strategic planning for introduction of

  • Pharma: in search of the sustainable ‘win win’ with the NHS Pharma: in search of the sustainable ‘win win’ with the NHS

    Fiona Bride. “We really recognise the need to look through the lens of the NHS when trying to understand how innovative medicines can benefit patients in the UK,” says Fiona. ... It comes back to what is our shared goal: focusing on patient outcomes

  • Lonely planet: why there is dwindling value in pharma travelling alone Lonely planet: why there is dwindling value in pharma travelling alone

    As governments explore new ways of finding efficiencies in the public purse, many are introducing value-based models that reimburse medicines based on the outcomes they deliver. ... In the process, the focus on demonstrating value has now reached fever

More from intelligence
Approximately 1 fully matching, plus 40 partially matching documents found.

Latest appointments

  • Redx poaches AstraZeneca senior executive Redx poaches AstraZeneca senior executive

    grow this company into a very excising and meaningful entity that has the potential to create both important new medicines for patients and generate significant value for shareholders.".

  • Sanofi appoints Dr Yong-Jun Liu as head of research Sanofi appoints Dr Yong-Jun Liu as head of research

    April. In his new role, Dr Liu will be responsible for all of the Paris-based pharmaceutical company's research and will be tasked with delivering innovative and high-value medicines.

  • ABPI Scotland appoints Sandra Auld as director ABPI Scotland appoints Sandra Auld as director

    the access to and use of new and innovative medicines for Scottish patients. . ... The ABPI Scotland team is fully committed to working with all of our stakeholders to support a common understanding and appreciation of the life-saving and life-enhancing

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Fishawack Group of Companies

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...

Latest intelligence

The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Escaping the spin cycle of sub-optimal launch
...

Quick links

Infographics

Multimedia